“…Preclinical PET imaging studies were approved by the Animal Care Committee at CAMH (Animal Use Protocol #838). Six adult Sprague-Dawley rats were scanned for 120 min on either a Mediso nanoScan PET/MR 3 T or PET/CT scanner (Budapest, Hungary), and the images were analyzed using VivoQuant® software (version 4.1, Invicro LLC, Needham, MA, USA), as described previously [20]. Five rats (3 M/2F, 528 ± 46 g ) were used for the baseline [ 18 F]SynVesT-1 scans (injected dose: 13.3 ± 3.2 MBq ; molar activity: 157 ± 64 GBq / μ mol ; mass injected: 0.22 ± 0.08 nmol / kg ), with two of the male rats also scanned after injection of the blocking drug levetiracetam (cat#L1784, LKT Laboratories Inc, St Paul, MN, USA) at 30 mg/kg (i.v., 15 min before the tracer; injected dose: 10.2 ± 0.1 MBq ; molar activity: 78 ± 15 GBq/ μ mol; injected mass: 0.24 ± 0.04 nmol/kg).…”